A few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change ...

With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial ...

The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is ...

Encoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial ...

Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for ...

The FDA’s proposal to offer 50% off application fees for drugs with early-stage trials conducted in the U.S. is unlikely to ...

Looking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.

Last month, biotech and pharma companies making or planning workforce cuts included three whose reductions will more than halve their workforces. Blueprint Medicines’ layoffs will affect the most ...

The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion ...

Months before the current biotech IPO boom, public investors began a more confident trek back into the sector, signaling the ...

The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked ...

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...